Comprehensive analysis of publications concerning combinations of immunotherapy and targeted therapies for hepatocellular carcinoma: a bibliometric study
BackgroundHepatocellular carcinoma (HCC), a prevalent malignancy, is often diagnosed at advanced stages. Recent advances have integrated immunotherapy with targeted therapy, significantly improving treatment outcomes. This study provides a bibliometric overview of these therapeutic combinations, eva...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1476146/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823856560754917376 |
|---|---|
| author | Biling Gan Lei Wu Shunan Zhou Zhihong Chen Fan Wu Lianqun Xu Zhenrong Chen Honghui Ma Peijia He Dan Fang Ning Shi |
| author_facet | Biling Gan Lei Wu Shunan Zhou Zhihong Chen Fan Wu Lianqun Xu Zhenrong Chen Honghui Ma Peijia He Dan Fang Ning Shi |
| author_sort | Biling Gan |
| collection | DOAJ |
| description | BackgroundHepatocellular carcinoma (HCC), a prevalent malignancy, is often diagnosed at advanced stages. Recent advances have integrated immunotherapy with targeted therapy, significantly improving treatment outcomes. This study provides a bibliometric overview of these therapeutic combinations, evaluating their development and impact.MethodsA rigorous selection process was applied to relevant literature from Web of Science, followed by in-depth bibliometric analyses— including timeline visualization, burst detection, and co-occurrence analysis—using CiteSpace and VOSviewer. This approach offered insights into the contributions of countries, institutions, authors, journals, references, and key terms within the field.ResultsA total of 506 studies published between 2014 and 2023 were included, with all articles in English. Mainland China dominated the publication output, contributing 40% (N = 202), followed by significant contributions from the United States and Japan. Kindai University led institutional contributions, accounting for 7.9% of the total (N = 40). The authors Kudo Masatoshi and Hatanaka Takeshi were the most prolific, each with nine publications. The journal Cancers emerged as the top publisher, with 48 relevant articles and an Impact Factor of 5.2 in 2022. A co-citation network analysis traced the evolution of immunotherapy and targeted therapy combinations in HCC treatment. Early research primarily focused on angiogenesis, dendritic cells, and expression markers, while recent trends have shifted towards phase III trials, adverse reactions, and checkpoint inhibitors, underscoring the field’s dynamic progression.ConclusionFuture research will expand on the pathological mechanisms underlying these therapies and novel interventions and combination strategies. Addressing adverse events and treatment discontinuation will remain central to advancing clinical applications. |
| format | Article |
| id | doaj-art-18c4f323bf23452991b8b9667f22e4a4 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-18c4f323bf23452991b8b9667f22e4a42025-02-12T07:25:40ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.14761461476146Comprehensive analysis of publications concerning combinations of immunotherapy and targeted therapies for hepatocellular carcinoma: a bibliometric studyBiling Gan0Lei Wu1Shunan Zhou2Zhihong Chen3Fan Wu4Lianqun Xu5Zhenrong Chen6Honghui Ma7Peijia He8Dan Fang9Ning Shi10Department of Hepatobiliary Surgery, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, ChinaGuangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, ChinaDepartment of Hepatobiliary Surgery, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, ChinaDepartment of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaGuangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, ChinaDepartment of Hepatobiliary Surgery, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, ChinaGuangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, ChinaGuangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, ChinaSchool of Medicine South China University of Technology, Guangzhou, Guangdong, ChinaDepartment of Hepatobiliary Surgery, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, ChinaDepartment of Hepatobiliary Surgery, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, ChinaBackgroundHepatocellular carcinoma (HCC), a prevalent malignancy, is often diagnosed at advanced stages. Recent advances have integrated immunotherapy with targeted therapy, significantly improving treatment outcomes. This study provides a bibliometric overview of these therapeutic combinations, evaluating their development and impact.MethodsA rigorous selection process was applied to relevant literature from Web of Science, followed by in-depth bibliometric analyses— including timeline visualization, burst detection, and co-occurrence analysis—using CiteSpace and VOSviewer. This approach offered insights into the contributions of countries, institutions, authors, journals, references, and key terms within the field.ResultsA total of 506 studies published between 2014 and 2023 were included, with all articles in English. Mainland China dominated the publication output, contributing 40% (N = 202), followed by significant contributions from the United States and Japan. Kindai University led institutional contributions, accounting for 7.9% of the total (N = 40). The authors Kudo Masatoshi and Hatanaka Takeshi were the most prolific, each with nine publications. The journal Cancers emerged as the top publisher, with 48 relevant articles and an Impact Factor of 5.2 in 2022. A co-citation network analysis traced the evolution of immunotherapy and targeted therapy combinations in HCC treatment. Early research primarily focused on angiogenesis, dendritic cells, and expression markers, while recent trends have shifted towards phase III trials, adverse reactions, and checkpoint inhibitors, underscoring the field’s dynamic progression.ConclusionFuture research will expand on the pathological mechanisms underlying these therapies and novel interventions and combination strategies. Addressing adverse events and treatment discontinuation will remain central to advancing clinical applications.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1476146/fullhepatocellular carcinomaimmunotherapytargeted therapycombination therapybibliometric studyVOSviewer |
| spellingShingle | Biling Gan Lei Wu Shunan Zhou Zhihong Chen Fan Wu Lianqun Xu Zhenrong Chen Honghui Ma Peijia He Dan Fang Ning Shi Comprehensive analysis of publications concerning combinations of immunotherapy and targeted therapies for hepatocellular carcinoma: a bibliometric study Frontiers in Immunology hepatocellular carcinoma immunotherapy targeted therapy combination therapy bibliometric study VOSviewer |
| title | Comprehensive analysis of publications concerning combinations of immunotherapy and targeted therapies for hepatocellular carcinoma: a bibliometric study |
| title_full | Comprehensive analysis of publications concerning combinations of immunotherapy and targeted therapies for hepatocellular carcinoma: a bibliometric study |
| title_fullStr | Comprehensive analysis of publications concerning combinations of immunotherapy and targeted therapies for hepatocellular carcinoma: a bibliometric study |
| title_full_unstemmed | Comprehensive analysis of publications concerning combinations of immunotherapy and targeted therapies for hepatocellular carcinoma: a bibliometric study |
| title_short | Comprehensive analysis of publications concerning combinations of immunotherapy and targeted therapies for hepatocellular carcinoma: a bibliometric study |
| title_sort | comprehensive analysis of publications concerning combinations of immunotherapy and targeted therapies for hepatocellular carcinoma a bibliometric study |
| topic | hepatocellular carcinoma immunotherapy targeted therapy combination therapy bibliometric study VOSviewer |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1476146/full |
| work_keys_str_mv | AT bilinggan comprehensiveanalysisofpublicationsconcerningcombinationsofimmunotherapyandtargetedtherapiesforhepatocellularcarcinomaabibliometricstudy AT leiwu comprehensiveanalysisofpublicationsconcerningcombinationsofimmunotherapyandtargetedtherapiesforhepatocellularcarcinomaabibliometricstudy AT shunanzhou comprehensiveanalysisofpublicationsconcerningcombinationsofimmunotherapyandtargetedtherapiesforhepatocellularcarcinomaabibliometricstudy AT zhihongchen comprehensiveanalysisofpublicationsconcerningcombinationsofimmunotherapyandtargetedtherapiesforhepatocellularcarcinomaabibliometricstudy AT fanwu comprehensiveanalysisofpublicationsconcerningcombinationsofimmunotherapyandtargetedtherapiesforhepatocellularcarcinomaabibliometricstudy AT lianqunxu comprehensiveanalysisofpublicationsconcerningcombinationsofimmunotherapyandtargetedtherapiesforhepatocellularcarcinomaabibliometricstudy AT zhenrongchen comprehensiveanalysisofpublicationsconcerningcombinationsofimmunotherapyandtargetedtherapiesforhepatocellularcarcinomaabibliometricstudy AT honghuima comprehensiveanalysisofpublicationsconcerningcombinationsofimmunotherapyandtargetedtherapiesforhepatocellularcarcinomaabibliometricstudy AT peijiahe comprehensiveanalysisofpublicationsconcerningcombinationsofimmunotherapyandtargetedtherapiesforhepatocellularcarcinomaabibliometricstudy AT danfang comprehensiveanalysisofpublicationsconcerningcombinationsofimmunotherapyandtargetedtherapiesforhepatocellularcarcinomaabibliometricstudy AT ningshi comprehensiveanalysisofpublicationsconcerningcombinationsofimmunotherapyandtargetedtherapiesforhepatocellularcarcinomaabibliometricstudy |